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Abstract
Introduction: Accumulating evidence suggests that both levels and activity of the estrogen receptor (ER) and the 
progesterone receptor (PR) are dramatically influenced by growth-factor receptor (GFR) signaling pathways, and that 
this crosstalk is a major determinant of both breast cancer progression and response to therapy. The 
phosphatidylinositol 3-kinase (PI3K) pathway, a key mediator of GFR signaling, is one of the most altered pathways in 
breast cancer. We thus examined whether deregulated PI3K signaling in luminal ER+ breast tumors is associated with ER 
level and activity and intrinsic molecular subtype.
Methods: We defined two independent molecular signatures of the PI3K pathway: a proteomic (reverse-phase 
proteomic array) PI3K signature, based on protein measurement for PI3K signaling intermediates, and a PI3K 
transcriptional (mRNA) signature based on the set of genes either induced or repressed by PI3K inhibitors. By using 
these signatures, we scored each ER+ breast tumor represented in multiple independent expression-profiling datasets 
(four mRNA, n = 915; one protein, n = 429) for activation of the PI3K pathway. Effects of PI3K inhibitor BEZ-235 on ER 
expression and activity levels and cell growth were tested by quantitative real-time PCR and cell proliferation assays.
Results: Within ER+ tumors, ER levels were negatively correlated with the PI3K activation scores, both at the proteomic 
and transcriptional levels, in all datasets examined. PI3K signature scores were also higher in ER+ tumors and cell lines of 
the more aggressive luminal B molecular subtype versus those of the less aggressive luminal A subtype. Notably, BEZ-
235 treatment in four different ER+ cell lines increased expression of ER and ER target genes including PR, and treatment 
with IGF-I (which signals via PI3K) decreased expression of ER and target genes, thus further establishing an inverse 
functional relation between ER and PI3K. BEZ-235 had an additional effect on tamoxifen in inhibiting the growth of a 
number of ER+ cell lines.
Conclusions: Our data suggest that luminal B tumors have hyperactive GFR/PI3K signaling associated with lower ER 
levels, which has been correlated with resistance to endocrine therapy. Targeting PI3K in these tumors might reverse 
loss of ER expression and signaling and restore hormonal sensitivity.
Introduction
Hormone therapy for breast cancer represents one of the
earliest targeted therapies and continues to be one of the
most effective therapies in breast cancer [1]. However,
only about 60% to 70% of patients with ER+  tumors
respond to therapy [2]. Given that the majority of diag-
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nosed breast cancers are ER+, this leaves a large subset of
breast cancers that do not respond to hormone therapy
and are subsequently often treated with chemotherapy.
Basic and clinical studies have shown the critical impor-
tance of the steroid receptor estrogen receptor (ER) and
progesterone receptor (PR) in the development of the
normal mammary gland and in the development and pro-
gression of breast cancer [3,4]. Loss or reduced expres-
sion of either of these receptors is associated with worse
prognosis and reduced response to antiestrogen therapy
[5]. It also has become clear that both levels and activity
of ER and PR are dramatically influenced by growth fac-
tor receptor (GFR) signaling pathways and that this cross-
talk is a major determinant of both breast cancer
progression and response to therapy [6,7].
Early studies identified PI3K activity associated with
viral oncogenes and led to its identification as a major sig-
naling pathway in cancer and a key mediator of GFR sig-
naling [8-10]. The PI3K pathway is now recognized to be
one of the most altered pathways in human breast cancer.
For example, breast tumors show mutation or loss of
PTEN or both, amplification and activating mutations in
PIK3CA, amplification of Akt2 and p70S6kinase, and
overexpression of Akt3 [11]. When the more-global pic-
ture of upstream and downstream PI3K signaling is taken
into account (for example, amplification or mutation of
upstream GFRs, mutation of insulin receptor substrates
(IRSs), and mutation of NF-κB), this points to the PI3K
pathway as being one of the most critical determinants in
breast cancer initiation and progression [12]. Consistent
with the mutational spectrum of PI3K signaling interme-
diates in breast cancer, direct analysis of PI3K activation
has shown an association with poor outcome [13-19].
Similarly, loss of PTEN is associated with low ER and PR
and poor outcome [20-22]. A recent report showed the
significance of downregulation of key molecules in the
PI3K pathway in response to aromatase-inhibitor ther-
apy, further emphasizing the predictive and therapeutic
role of this pathway in hormonal therapy [23].
In this study, we addressed the question whether ele-
vated PI3K decreases ER levels and activity to cause hor-
mone resistance within the ER+ subset of human breast
cancer. We hypothesized that this loss of ER expression
or function or both may be reversed by inhibition of
PI3K, which might allow better subsequent therapeutic
targeting by using a combination of PI3K inhibitors and
antiestrogens. Our approach in examining human breast
tumors and cell lines was to use gene-expression and pro-
teomic profiling data to define molecular signatures of
PI3K and then to use these signatures as a surrogate for
PI3K activity. PI3K signaling is manifested at both protein
and transcription levels, whereby the signal initiated by
GFR is transduced by phosphorylation of signaling pro-
teins, eventually leading to changes in gene transcription.
Therefore, we defined two different PI3K molecular sig-
natures: (a) a PI3K protein signature (by reverse-phase
protein arrays, or RPPAs), and (b) a PI3K mRNA signa-
ture (by gene-expression array). Interestingly, both of
these signatures yielded similar associations in the
human tumor datasets examined.
Materials and methods
Human breast tumor samples
The human ER+ breast tumors were obtained from tumor
banks after pathologist review under the auspices of
Institutional Review Board-approved protocols at Hospi-
tal Clinico Universitario de Valencia (Valencia, Spain),
the University of Texas M. D. Anderson Cancer Center,
and Baylor College of Medicine. Informed consent was
obtained from all patients involved. Preparation of the
tumor samples for protein analysis and characterization
of ER status was carried out as previously described [24].
Reverse phase proteomic arrays
RPPA, as performed in our group, has been described
previously [25,26] and was used to quantify PTEN
expression and phosphorylation of AKT at Thr308 and
Ser473, glycogen synthase kinase 3 (GSK3) at Ser21, mam-
m a l i a n  t a r g e t  o f  r a p a m y c i n  ( m T O R )  a t  S e r 2448, and
p70S6K at Thr389 as a ratio to total expression of each
protein by using antibodies from cell signaling (total
PTEN and all phosphospecific antibodies). For each pro-
tein, normalized expression values were centered across
the ER+ tumors on the mean (overall findings observed
were the same when centering values on the median ver-
sus the mean; results not shown). The protein lysates
from breast cancer cell lines were obtained from the Law-
rence Berkeley National Laboratory at the University of
California at San Francisco.
Gene-expression analysis
Gene-transcription profiling datasets were obtained from
previous studies (CMap build01, [GEO:GSE5258]; van de
Vijver (available at [27]); Loi, [GEO:GSE9195]; Wang,
[GEO:GSE2034]; Desmedt, [GEO:GSE7390]; Neve (avail-
able at [28]). Of the 134 ER+ tumors in the Desmedt data-
set, 28 were also represented in the Loi dataset, and so
these were removed before computing the correlations
for Desmedt. The CMap dataset values were processed as
previously described [29]. Differentially expressed genes
were identified by using a two-sided t test on log-trans-
formed data, with the false discovery rate (FDR) esti-
mated by using the method of Storey et al. [30]. Java
TreeView [31] represented expression values as color
maps. To score each ER+ breast tumor for similarity to
our PI3K transcription signature, we derived a ''t score''
for the tumor in relation to the PI3K signature patterns,
as previously described [32,33]. In brief, the PI3K mRNACreighton et al. Breast Cancer Research 2010, 12:R40
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t score was defined as the two-sided t statistic comparing
the average of the PI3K-induced genes with that of the
repressed genes within each tumor (after first centering
the log-transformed values on the median across sam-
ples; Loi dataset: values centered to standard deviations
from the median within U133A and U133Plus2 array sub-
sets). The mapping of transcripts or genes between the
two array datasets was made on the Entrez Gene identi-
fier; where multiple human array probe sets referenced
the same gene, one probe set was picked at random to
represent the gene (for ER gene, the probe set 205225_at
was used for all Affymetrix array datasets).
For each gene-transcription profile dataset, we scored
the ER+ tumors for luminal A versus luminal B subtype,
essentially as previously described [34], by using the data-
set from Hoadley et al. [35] to define luminal A versus B
expression patterns. In brief, for each gene common to
the Hoadley platform and the other breast-array dataset
platform, we computed the mean centroid of the luminal
A and B subtypes in the Hoadley dataset and centered
each group average on the centroid. We then took the
Pearson correlation (using all genes common to both
array datasets) between the Hoadley centered averages
and the expression values of each profile in the indepen-
dent dataset. For the ER+ tumors represented on the
RPPA dataset, we distinguished luminal A from luminal B
tumors, by using a previously established metric (unpub-
l i s h e d  d a t a ) ,  w h i c h  r e l i e d  o n  a  p a n e l  o f  m a r k e r s  f o r
assessing ERα function (ERα/PR/Bcl2), HER2 levels and
activity (HER2/HERp1248), apoptosis (cleaved caspase 7/
cleaved PARP/Bcl2), protein synthesis (p70S6K/S6 phos-
phorylation), cell-cycle progression (cyclin B1), and
stroma (collagen VI). The expression levels of these
markers from RPPA were weighted equally but in oppos-
ing directions for their association with either the luminal
A (positive weighting) or luminal B (negative weighting)
subtype and summed to create a classifier, by using the
predefined log mean centered "luminalness" score cutoff
of -0.907.
Cell cultures
All cell lines were obtained from the American Type Cul-
ture Collection (ATCC, Manassas, VA, USA). Cell lines
were cultured in RPMI 1640 (ATCC) (ZR75-1, BT483,
and ZR75-B), or DMEM (Invitrogen, Carlsbad, CA, USA)
(MCF7 and CAMA-1), supplemented with 10% heat-
inactivated fetal bovine serum (Thermo Scientific, Pitts-
burgh, PA, USA) and 1% penicillin-streptomycin-glu-
tamine (Invitrogen). Cell cultures were maintained in a
humidified atmosphere of 5% CO2 at 37°C. For the use of
PI3K inhibitor, BEZ-235 (Novartis) was added to the cul-
ture medium of a triplicate sample at a concentration of
100 nM  or 500 nM  at 3 hours before cell harvesting.
DMSO (Sigma, St. Louis, MO, USA) with 1:1,000 dilution
was used as the control. For the use of growth factor,
starved cells kept in serum-free medium for 24 hours
were first preincubated with DMSO (control) or BEZ-235
(100 nM, 500 nM) for 30 minutes, followed by adding 100
ng/ml of IGF-I or HCl (1:1,000 dilution) for another 3
hours before harvesting. For experiments involving estro-
gen deprivation, cells were cultured in phenol red-free
medium supplemented with 5% charcoal-stripped fetal
bovine serum (Thermo Scientific) for 48 hours before
treatment.
Quantitative real-time PCR
Total RNA was extracted with an RNeasy Mini kit (Qia-
gen, Hilden, Germany). One microgram RNA of each
sample was reverse transcribed in a 20-μl reaction by
using 200 U superscript II reverse transcriptase and ran-
dom hexamers (Invitrogen). Target primer sequences are
as follows: ER-α  forward AACCGAGATGATGTAGC-
CAGC, reverse, CAGGAACCAGGGAAAATGTG; PR
forward GATGCTGTATTTTGCACCTGATCTA,
reverse GAACTCTTCTTGGCTAACTTGAAGCT;
CAV1 forward GGTCAACCGCGACCCTAAA, reverse
CCTTCCAAATGCCGTCAAA; IGF1R forward CAC-
GACGGCGAGTGCAT, reverse ACAGACCTTCG-
GGCAAGGA. QPCR was performed on an ABI Prism
7500 Sequence Detection System by using SYBR Green
PCR Master Mix (ABI, Foster City, CA, USA) in a 20-μl
reaction and human β-actin (ACTB) as an endogenous
control. The 20-μl reactions were incubated in a 96-well
optical plate at 95°C for 10 minutes, followed by 40 cycles
of 95°C for 15 seconds, and 60°C for 35 seconds. Fold
changes in mRNA expression between treatments and
controls were determined by the 2-ΔΔCt method [36]. Dif-
ferences between comparison groups were determined
with a two-sided Student t test and one-way ANOVA.
Error bars on plots represent ± standard error of the
mean (SEM), unless otherwise noted.
Growth-inhibition assays
All experiments were done in 96-well plates. Cells in qua-
druplicate wells were grown in regular medium and
tamoxifen (Tam), BEZ-235, or Tam + BEZ-235 were
added directly into each well. After 4 days, 0.05% methyl-
ene blue (Sigma) staining was performed, and the absor-
bance value at 650 nm was acquired by microplate reader
(model 680; Bio-Rad). Growth inhibition (%) was calcu-
lated by the formula of (1 - ODtreated/mean(ODcontrol)) ×
100%. Error bars for each group plotted denote the stan-
dard deviation (SD) from four independent samples. Dif-
ferences between comparison groups were determined
with two-sided Student t test and one-way ANOVA.
Results
A PI3K proteomic signature is associated with lower ER 
levels in ER+ breast tumors
We defined a protein signature of the PI3K pathway in
human ER+ breast tumors by using RPPA to measure the
phosphorylation states as well as total levels of key signal-Creighton et al. Breast Cancer Research 2010, 12:R40
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ing intermediates of the pathway. For each of 429 ER+
tumors represented on the arrays, we computed a PI3K
score (Figure 1a), which was the sum of the phosphopro-
tein levels (mean-centered across tumors) of Akt, mTOR,
GSK3, S6K, and S6, minus the total levels of pathway
inhibitor PTEN (that is, PI3K score = pAkt + pmTOR +
pGSK3 + pS6K + pS6-PTEN); a high PI3K score would
indicate high pathway activity. Within the ER+ tumors,
Figure 1 Proteomic and transcriptomic signatures of PI3K signaling are associated in ER+ breast tumors with lower ER and PR levels and 
the luminal B subtype. (a) Heat map of PI3K proteomic signature proteins in 429 ER+ human breast tumors, along with corresponding patterns for 
ER and PR (blue ER on the color scale meaning lower levels, although still present) and intrinsic molecular subtype association (luminal A versus lumi-
nal B). PI3K protein score is the sum of the phosphoprotein levels of Akt, mTOR, GSK3, S6K, and S6, minus the total levels of pathway-inhibitor PTEN. 
Tumors are ranked from low to high PI3K score, where a high PI3K score indicates high pathway activity. (b) PI3K transcriptomic (that is, mRNA) sig-
nature genes in 226 ER+ breast tumors (from van de Vijver et al.), along with ER and PR mRNA; tumors are ranked from low to high PI3K mRNA score. 
(c) Spearman's correlations between PI3K score and ER/PR in multiple expression-profiling datasets (four transcriptomic, one proteomic). For pro-
teomic dataset, PI3K protein score and ER/PR protein levels were analyzed; for mRNA datasets, PI3K mRNA score and ER/PR mRNA. (d) In each of the 
five expression datasets, the average PI3K score in ER+ tumors of the luminal B subtype was compared with the average in ER+ tumors of the luminal 
A subtype by t test.Creighton et al. Breast Cancer Research 2010, 12:R40
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PI3K protein signature scores were inversely correlated
with ER protein levels, which pattern could be discernible
by eye from heat maps of the data (Figure 1a), as well as
being statistically significant (Spearman's R = -0.29; P <
1E-09). In addition to ER, ER-inducible PR was also anti-
correlated with the PI3K score (Spearman's R = -0.21; P <
5E-06).
A PI3K transcriptomic signature is associated with lower ER 
levels in ER+ breast tumors
In addition to a proteomic signature of PI3K signaling, we
defined a PI3K transcriptomic signature, representing the
set of gene transcripts induced or repressed as a result of
the PI3K pathway, and applied this signature to human
tumors. We examined the public "Connectivity Map," or
"CMap," dataset, which consists of gene-expression pro-
files in response to treatment by 164 different small-mol-
ecule inhibitors [37]. We compared cells treated with
inhibitors for PI3K (specifically, wortmannin or LY-
294002) with cells treated with other small molecule
inhibitors, to define a gene-transcription signature of
PI3K-inhibited cells (P < 0.01; FDR < 0.1, Supplemental
figure S1 in Additional file 1), which consisted of 2,221
Affymetrix probe sets (755 unique genes induced by the
inhibitors, 1,046 genes repressed; complete gene list in
Additional file 2). In addition to the CMap PI3K signa-
ture, we also considered two other gene signatures, one of
PTEN loss in human breast tumors [38] and another of
Akt overexpression in mouse [13,39]. We found that
these three signatures were highly correlated with each
other in terms of the same breast-tumor samples showing
high PI3K activity (Supplemental Table 1 in Additional
file 1), although all subsequent results shown here make
use of the CMap signature.
We applied the CMap PI3K mRNA signature to a pub-
lic gene-expression profile dataset of 226 human ER+
breast tumors from van de Vijver et al. [40], scoring each
tumor for PI3K signature manifestation (Figure 1b). As
the CMap patterns were of PI3K inhibition, those tumors
positively correlated with these patterns were inferred to
have low PI3K activity, and those tumors anticorrelated
with these patterns were inferred to have high PI3K activ-
ity. Within the van de Vijver ER+ tumors, the PI3K mRNA
signature scores (a high score indicating high pathway
activity) were inversely correlated with ER mRNA levels.
These patterns could be discernible by eye (Figure 1b) as
well as being statistically significant (Spearman R = -0.32,
P < 1E-06). In addition to the van de Vijver dataset, we
examined three other independent gene-expression data-
sets of ER+ tumor from other studies [41-43], in which a
pattern of inverse correlation between PI3K score and ER
mRNA was statistically significant there as well (Figure
1c). PR mRNA was also significantly anticorrelated with
the PI3K score in three of the four mRNA datasets (P <
0.05) and was trending toward significance in the fourth
dataset (P = 0.07) (Figure 1c). In summary, the associa-
tion of high PI3K activity with lower ER and PR appeared
to be quite robust, and the results of the PI3K mRNA sig-
nature agreed with those of the PI3K protein signature.
PI3K proteomic and transcriptomic signatures are 
associated with the luminal B molecular subtype of ER+
Gene-expression profiling of human breast tumors has
been used to classify them into several distinct and clini-
cally relevant groups (basal-like, luminal A, luminal B,
HER2+/ER-, and normal-like) [44]. In particular, ER+
tumors can be subdivided into the less-aggressive luminal
A subtype and the more-aggressive luminal B subtype. In
each of the expression datasets examined (four transcrip-
tomic, one proteomic), we scored the ER+ tumors for
luminal B versus luminal A subtype, and we found that
the PI3K signature scores (both protein and mRNA) were
significantly higher in luminal B tumors (Figure 1d). Fur-
thermore, in the two transcriptomic datasets for which
patient-outcome and patient-treatment information were
available (van de Vijver and Loi), the PI3K mRNA signa-
ture predicted worse prognosis in ER+ tumors (Supple-
mental figure S2 in Additional file 1); this trend of worse
prognosis for tumors with high PI3K score also was evi-
dent in the subset of patients that received hormone ther-
apy as well as in untreated patients.
PI3K proteomic and transcriptomic signatures are 
correlated within breast cancer cell lines
W e  w e n t  o n  t o  e x a m i n e  t h e  P I 3 K  s i gn a t u r es  i n  b r eas t
cancer cell lines, where we had both gene-expression data
(from Neve et al. [45]) and proteomic data (from our
group) on the same set of 40 cell lines. Even given this
limited number, the PI3K protein score correlated signifi-
cantly (albeit not perfectly) with the PI3K mRNA score
across all cell lines (Spearman's R = 0.35; P = 0.013; Figure
2a), as well as within the subset of cell lines previously
defined as "luminal" (that is, associated with ER+) in sub-
type (n = 18; R = 0.46; P = 0.029; Figure 2b). In addition,
we scored the 25 luminal cell lines in the Neve mRNA
dataset for similarity to the luminal B versus luminal A
subtype patterns, and, as observed in the tumors, the
PI3K mRNA scores in luminal cell lines tended to associ-
ate with luminal B (R = 0.57; P = 0.001; Figure 2b). Of the
luminal cell lines examined here, 12 were recently exam-
ined in a previous study, for mutations in PTEN  and
PIK3CA  [24]; however, as 11 of the 12 cell lines were
found to harbor mutations in either one of the two genes,
no correlations were apparent between PI3K pathway
alteration by mutation and luminal B or PI3K signature
scores.Creighton et al. Breast Cancer Research 2010, 12:R40
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Modulation of PI3K signaling in breast cancer cell lines has 
an inverse effect on levels of ER and ER-inducible genes
Although our analysis of molecular signature patterns of
PI3K in human tumors showed at least a correlative
(inverse) relation between PI3K and ER, we could also
demonstrate a functional  relation between the two, by
using cell-culture models. With gene-profiling data from
cell lines (Figure 2), we selected a number of cell lines for
further functional studies, including ZR75-B and CAMA-
1, which scored highly for both PI3K and luminal B
expression patterns, and ZR75-1 and BT483, which had
low PI3K scores and associated more with luminal A. In
many systems, IGF-I (through its receptor IGF-IR) is a
potent activator of PI3K [46]. We previously showed in
MCF-7 cells that IGF-I activates PI3K/Akt/mTOR to
downregulate PR mRNA levels rapidly through direct
inhibition of PR promoter [46]. Similarly, we report here
that treatment of MCF-7 cells with IGF-I caused a dose-
dependent rapid reduction in ER mRNA levels within 3
hours, and this reduction remained constant over a 24-
hour period (Figure 3a). This downregulation was dose
responsive (Figure 3b), and the rapid reduction was a
direct effect of IGF-I, as it was not affected by incubation
of the cells with cycloheximide (Figure 3c) and thus does
Figure 2 PI3K protein and mRNA activation scores correlate with each other and with the luminal B subtype in breast cancer cell lines. (a) 
Scatterplot of PI3K protein score versus PI3K mRNA score in 40 breast cancer cell lines. (b) Luminal breast cancer cell lines (as defined by Neve et al.) 
plotted alongside their PI3K mRNA score (left) and their PI3K protein score (middle), along with their correlation with a luminal B signature from Hoad-
ley et al. (right). Note that some of the cell lines were not analyzed by proteomics and are indicated (*). Correlations (R values) by Spearman's.Creighton et al. Breast Cancer Research 2010, 12:R40
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not require new protein translation. We also found in two
additional cell lines tested (ZR75-1 and BT483) that IGF-
I decreased expression of ER and ER target genes PR and
CAV1 (Figure 3d).
Consistent with the preceding section, inhibiting PI3K
had the opposite effect on the ER from stimulating the
PI3K pathway by IGF-I. In four different ER+ breast can-
cer cell lines tested (two of them luminal A and two of
them luminal B), treatment with PI3K inhibitor BEZ-235
for 3 hours significantly increased expression of ER and
ER-inducible target genes (PR, CAV1, and IGF1R); this
result was observed by using two concentrations of the
inhibitor (100 nM and 500 nM), with the higher concen-
tration appearing to have a slightly more dramatic effect
on the genes (Figure 4a). As expected, BEZ-235 downreg-
ulated phosphorylation of key PI3K signaling intermedi-
Figure 3 PI3K-activator IGF-I rapidly downregulates mRNA levels of ER and ER target genes. (a) MCF-7 breast cancer cells were starved in SFM 
and then incubated with IGF-I (100 ng/ml, 8 nM) for 3 or 24 hours. RNA was isolated, and ER mRNA levels were measured with QRT-PCR (± SEM). (b) 
MCF-7 cells were incubated with an increasing dose of IGF-I, and ER mRNA levels were measured as in part (a). (c) ER levels in MCF-7 cells incubated 
with (+) or without (-) cycloheximide and stimulated with or without IGF-I (100 ng/ml) for 3 hours. (d) In two additional cell lines (ZR75-1 and BT483), 
expression levels of ER and ER target genes (PR and CAV1) after IGF-I treatment (100 ng/ml for 3 hours). All comparisons shown here between IGF-I 
(100 ng/ml) and control (± SD) were significant, with P ≤ 0.05.Creighton et al. Breast Cancer Research 2010, 12:R40
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ates included in our PI3K protein signature
(Supplemental figure S3 in Additional file 1). Interest-
ingly, in addition, BEZ-235 had a suppressive effect on
estrogen-driven cell growth (Supplemental figure S4 in
Additional file 1), indicating that ER signaling is also at
least somewhat dependent on PI3K; this can be partly
explained by the fact that plasma-membrane-associated
ER (acting nongenomically) is able to activate various
GFRs and PI3K [47].
Consistent with IGF-I-reducing levels of ER through
the PI3K pathway, treatment of IGF-I-stimulated cells
with BEZ-235 could increase levels of ER and ER target
genes relative to their IGF-I-repressed levels (Figure 4b),
showing that PI3K is required for IGF-I-mediated down-
regulation of ER expression and activity on classic ER-
dependent gene transcription. Similar results were found
with MCF-7 cells (data not shown). Increasing ER levels
and activity by inhibiting PI3K should presumably
increase hormone sensitivity, and in four different cell
lines tested (two of them luminal A, and two of them
luminal B), the combination of BEZ-235 and tamoxifen
inhibited growth more than either tamoxifen alone or
BEZ-235 alone (Figure 5).
Discussion
In this study, we found that GFR/PI3K signaling is associ-
ated in ER+ breast cancers with relatively lower ER levels
and with the luminal B molecular subtype. It is worthy of
note that the lower ER levels in those ER+ tumors with
high PI3K activity were still detectable, as these tumors
were still clinically defined as ER+. Evidence for the link
between PI3K and ER was found here both by using
molecular "signatures" of PI3K to probe human ER+
tumors and by manipulating the PI3K pathway in cell-
culture models. Importantly, ER levels and activity could
be increased in cell cultures by blocking the PI3K path-
way. Our interpretation of these data is that some ER+
tumors rely more heavily on GFR/PI3K signaling than on
estrogen for growth, and that by blocking PI3K, these
tumors would be forced to resort to the alternative estro-
gen-signaling pathway for continued growth; by blocking
both PI3K and estrogen pathways together, therefore, the
tumor may be left with even fewer options.
As the luminal B subtype is the much more aggressive
subtype of ER+ breast cancer [44], targeting PI3K in these
tumors might reverse loss of ER expression and signaling
and restore hormonal sensitivity. In addition to luminal B
ca nc e rs,  m an y  bas a l-l ik e  ( ER -/PR-/HER2-) cancers have
loss or mutation of PTEN and high PI3K activity [11,33],
and some (though not all) basal cancers can reactivate the
ER in response to GFR inhibition [48]. The two ER- cell
lines we have examined to date (MDA-MB-231 and
MDA-MB-468) did not reexpress ER in response to BEZ-
235 (data not shown), although this could be another ave-
nue for future work.
In selecting luminal/ER+ cell lines for study, one could
conceivably use our scoring for PI3K signature activation
Figure 4 Inhibition of PI3K signaling increases mRNA levels of ER 
and ER-inducible genes. (a) QRT-PCR results showing increased ex-
pression of ER and ER target genes (PR, CAV1, and IGF1R) in four differ-
ent cell lines, after treatment with PI3K inhibitor BEZ-235 (100 nM and 
500 nM for 3 hours). *Significant differences (P < 0.05; t test) between 
BEZ-235 and control (multiple comparisons expected to yield 32 × 
0.05/23 = 7% false positives). Twelve of the 16 marker/cell-line combi-
nations individually significant (P < 0.05) by ANOVA (P > 0.05: PR/ZR75-
B, PR/ZR75-1, CAV1/BT483, IGF1R/ZR75-1; false-positive rate: 16 × 0.05/
12 = 7%). (b) IGF-I-mediated downregulation of ER and ER target genes 
is restored by inhibition of PI3K. ZR75-1 and BT483 cells were preincu-
bated for 30 minutes with or without BEZ-235 (100 and 500 nM) and 
then stimulated with or without IGF-I (100 ng/ml) for 3 hours. ER and 
ER targets gene mRNA levels were measured with QRT-PCR (data from 
DMSO and IGF-I + DMSO groups also are featured in Figure 3a). *Signif-
icant differences from corresponding IGF-I + DMSO group (P ≤ 0.05; t 
test). All marker/cell-line combinations were significant (P < 0.03) by 
ANOVA.Creighton et al. Breast Cancer Research 2010, 12:R40
http://breast-cancer-research.com/content/12/3/R40
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as a guide, although it remains to be seen how cell lines
with high PI3K scores might behave differently from cell
lines with low scores. One could hypothesize that PI3K
scores are an indicator of response to therapies targeting
the PI3K pathway; however, to date, we have not found
evidence of this in our 2-D culture models. In one recent
study by Brachmann et al. [49], a panel of breast tumor
cell lines was treated with BEZ-235; however, as the
Figure 5 PI3K inhibitor BEZ-235 has an additional effect on tamoxifen (Tam) in ER+ cell lines. Growth-inhibition assays for luminal B-cell lines 
ZR75-B and CAMA-1 and luminal A cell lines BT483 and ZR75-1, treated for 4 days with Tam (100 nM), BEZ-235 (10 nM), or the combination of Tam + 
BEZ-235. Average growth inhibition normalized to control (regular medium) in each cell line (± SD). *Significant differences from Tam + BEZ-235 group 
(P < 0.05; t test). For each cell line, significant differences exist among the groups by ANOVA (P < 1E-5).Creighton et al. Breast Cancer Research 2010, 12:R40
http://breast-cancer-research.com/content/12/3/R40
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observed 50% growth inhibition (GI-50) values were all in
the low nanomolar range, the authors concluded that
BEZ-235-induced growth inhibition in the 2-D setting
was not amenable for stratification prediction. Consistent
with this notion, we obtained the GI-50 values from
Brachmann et al., but could not find any trend for corre-
lation with our PI3K scores (neither protein nor mRNA).
Furthermore, we made a point of manipulating the PI3K
pathway in both cell lines with high PI3K scores and cell
lines with low scores, and both sets of cell lines appear to
yield similar results. It is important to keep in mind that
our PI3K scores represent a relative rather than an abso-
lute measure of PI3K activity, and it appears that the
functional relation between PI3K and ER exists to at least
some degree in most ER+ cancers. Nevertheless, the PI3K
scoring might prove relevant in model systems beyond 2-
D or in measures other than growth.
T h e  d y n a m i c  n a t u r e  o f  E R  a n d  P R  l e v e l s  i n  h u m a n
breast cancer, and the potential to alter levels for thera-
p e u t i c  be n e f i t ,  h a s  r e c e n t l y  g a i n e d  m u c h  i n t e r e s t  [ 4 8 ] .
Levels of ER are known to correlate significantly correlate
with patients' response to endocrine therapy, and quanti-
tative ER measurement with RT-PCR has been shown to
be the best single predictor of tamoxifen benefit [50].
Reduced expression or a complete loss of ER may occur at
multiple levels and by multiple mechanisms, from the
gene to the protein [51]. ER levels are controlled in a
homeostatic fashion by many interacting pathways. For
example, ER mRNA and protein can be downregulated in
MCF-7 cells by stably overexpressing EGFR or constitu-
tively activating erbB-2, Raf, or MEK [52]; and in a num-
ber of ER- breast cancers, ER expression can be restored
by inhibiting GFR through targeting of MAPK/ERK [48].
Of interest to this study, the Forkhead box class O (FoxO)
family members, which are known downstream targets of
PI3K, have recently been shown to play a major role in
modulating both ER levels and activity. For example,
FOXO3A (in our PI3K mRNA signature, one of the genes
showing repression by PI3K (i.e., induction by PI3K
inhibitors) can bind the ER promoter and increase ER
levels, and HER-2/Akt-mediated activation and translo-
cation of FOXO3A out of the nucleus results in a reduc-
tion of ER levels [53]. Interestingly, we found FOXO3A to
be underexpressed (based on gene array) in MCF-7 xeno-
graft tumors that had developed resistance to tamoxifen
[54]. Besides FOXO3A, other master transcription fac-
tors, including Snail, can modulate ER promoter activity
[55], and we have shown that IGF-IR through PI3K can
elevate Snail [56].
Conclusions
Our study implies that ER+ patients with high GFR/PI3K
signaling, who presumably are at greater risk of develop-
ing resistance to hormone therapy alone, may need to be
treated with GFR/PI3K-targeted therapy in addition to
hormone therapy. Clinical trials are currently under way
for PI3K inhibitors such as BEZ-235. As was found to be
the case with therapies targeting HER2 or ER, defining
the patient population most likely to respond to PI3K-tar-
geting therapy may well prove critical in establishing the
success of these new drugs. In this regard, clinical studies
of PI3K inhibitors that focus on the subset of ER+ patients
with either tumors of the luminal B molecular subtype
(which could be defined, for example, by using the
PAM50 clinical assay [57]) or a prediction of poor out-
come on hormone therapy alone (for example, as defined
by using the Genomic Health Index [58]), could provide
valuable information on targeting the PI3K pathway in
breast cancer.
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